SEC Form 4 · accession 0001144204-16-101713
Alliqua BioMedical, Inc. · ALQA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Ian Johnson
Officer — President and CEO · Director
Period of report
May 11, 2016
Accepted (ET)
May 13, 2016 · 3:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001054274
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2016 | A | 300,000 | $0.00 | A | 944,535 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a restricted stock award that is subject to forfeiture until vested. The award vests in three equal installments based on the Issuer's satisfaction of certain performance criteria prior to May 11, 2021, with one-third (1/3) of the awarded shares vesting on each date, if any, that the Issuer files a report with the SEC reporting audited annual gross revenues that equal or exceed each of $25 million, $30 million and $36 million, subject to the terms and conditions of the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan and that certain restricted stock award agreement by and between the Issuer and the reporting person, effective as of May 11, 2016.